EBRD takes part in the US$ 51 million private placement of Mabion S.A.

EBRD takes part in the US$ 51 million private placement of Mabion S.A.

Participation in private placement as a cornerstone investor

• EBRD participates in US$ 51m equivalent private placement of Mabion
• Mabion is leading biotechnology company in Poland
• EBRD to invest US$ 18 million (PLN 61.4 million)

LONDON, 26-Mar-2018 — /EuropaWire/ — The EBRD is participating in the US$ 51 million private placement of Mabion S.A., a leading biotechnology company in Poland. The Bank provided the equivalent of US$ 18m as a cornerstone investor together with PFR Life Science sp. z o.o. (part of the Polish Development Fund) and institutional investors specialised in healthcare and life sciences from the United States and Europe, reinforcing and diversifying Mabion’s shareholder base.

The successful placement today generated gross proceeds of PLN 175 million (or approximately US$ 51 million). The shares were sold at a price of PLN 91 per share. Guggenheim Securities, LLC acted as the sole placement agent for the shares to investors in the United States.

Mabion intends to use the net proceeds from the financing to cover the cost of the expansion of production capacity in Konstantynów Łódzki, Poland and costs and expenses related to the development and commercialisation of Mabion CD20, a biosimilar to rituximab with the potential as a novel treatment of multiple sclerosis.

The financing was structured as a sale by Mabion’s majority shareholder, Twiti Investments Ltd., of 1.920.772 existing ordinary bearer shares, admitted to trading on the Warsaw Stock Exchange, the aggregate proceeds of which will be immediately lent to Mabion pursuant to a loan agreement between Twiti and Mabion. The loan will be repaid through the issuance of 1.920.772 new ordinary bearer shares to Twiti subject to the approval of a capital increase at Mabion’s extraordinary general meeting to be held on 18 April 2018.

About Mabion

Mabion S.A. is a leading biotechnology company in Poland, created for the purpose of marketing cutting-edge biotechnological drugs based on humanised monoclonal antibodies. This technology, developed independently in Mabion, meets highest international standards. The process of humanising monoclonal antibodies, which is the pinnacle of modern biotechnology, allows for creation of targeted drugs which act selectively on tumour cells, thus ensuring greater effectiveness and lower toxicity of the therapy. Mabion is one of the few biopharmaceutical companies with the capacity for comprehensive development and implementation of all kinds of biotechnology drugs – starting with the design stage, through the selection of the platform and manufacturing technology, and ending with the manufacture and obtaining marketing authorisation of the finished drug. Currently, the company conducts research and development works on several biotech drugs used in the treatment of cancers and inflammatory diseases. More information is available on www.mabion.eu.

SOURCE: EBRD

MEDIA CONTACT

Tel: +44 20 7338 7805
Email: press@ebrd.com